GLENMARK PHARMACEUTICALS LIMITED
Overview
Located in the financial capital of India, Glenmark was founded by Gracias Saldanha as a
generic drug manufacturing company. It is the fifth-largest company in India with its market
including India, Russia, and Africa. Innovation, focusing on new drugs in the field of cancer,
dermatology, and respiratory diseases and their contribution towards society initiatives,
Glenmark is one such company in the pharmaceutical industry to look into.
Glenmark is known for its core values like its commitment to provide advanced patient care
and create a sustainable future, achieving their objectives, consistently striving to reach their
vision, respecting stakeholders, and empowering people.
Their corporate social responsibility initiative called “Joy of Giving”, encourage their
employees to take part in various social activities in their local communities and support
many foundations like the Boys & Girls Club of Hackensack and Lodi, Greater Bergen
Community Action, National Breast Cancer Foundation, The Centre for Food Action, Susan
G. Komen for the Cure.
One of the novel ideas by Glenmark is the manufacturing of steroids for seasonal allergy
which is nasal spray ryaltris. Also, in the fight against Covid-19, Glenmark has launched a
potential covid-19 vaccine under the name FabiFlu which found some base in the treatment
of Covid-19.
Working tirelessly for more than 40 years, Glenmark is determined to meet its scientific and
commercial goals with an established team that are known for innovation and creating
solutions for patient’s and doctor’s needs.
Shareholding pattern of the company
Summary:
Trend:
Management of the company
MR. GLENN SALDANHA,
CHAIRMAN & MANAGING DIRECTOR
Mr. Saldanha joined Glenmark in 1998 as Director and took over as Managing Director and
CEO in 2000. He transformed Glenmark into a truly global organization with revenues of
over $1.5 billion (US). Under his leadership, Glenmark has evolved from an Indian branded
generics business into a research-driven and innovation led organization. Mr. Saldanha’s
vision is to discover, develop and introduce India’s first innovative drug for the world.
MRS. CHERYLANN PINTO
EXEC. DIRECTOR-CORP SERVICES
Mrs. Pinto has been the Director of Corporate Affairs at Glenmark since October 1999 and is
an executive member of the Board. With over 30 years of experience in the pharmaceutical
field, she currently heads the company’s Corporate services, Insurance, IT, Admin, HR and
CSR functions. She had set up a pharmaceutical company where she served as the Managing
Director from 1989 to 1999 before joining Glenmark.
